Clinical standards for the management of adverse effects during treatment for TB
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft sta...
Uložené v:
| Vydané v: | The international journal of tuberculosis and lung disease Ročník 27; číslo 7; s. 506 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
France
01.07.2023
|
| Predmet: | |
| ISSN: | 1815-7920, 1815-7920 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.
65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.
We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.
These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment. |
|---|---|
| AbstractList | BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment.BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE.METHODS: 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards.RESULTS: We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research.CONCLUSION: These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment. Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE. 65/81 invited experts participated in a Delphi process using a 5-point Likert scale to score draft standards. We identified eight clinical standards. Each person commencing treatment for TB should: Standard 1, be counselled regarding AE before and during treatment; Standard 2, be evaluated for factors that might increase AE risk with regular review to actively identify and manage these; Standard 3, when AE occur, carefully assessed and possible allergic or hypersensitivity reactions considered; Standard 4, receive appropriate care to minimise morbidity and mortality associated with AE; Standard 5, be restarted on TB drugs after a serious AE according to a standardised protocol that includes active drug safety monitoring. In addition: Standard 6, healthcare workers should be trained on AE including how to counsel people undertaking TB treatment, as well as active AE monitoring and management; Standard 7, there should be active AE monitoring and reporting for all new TB drugs and regimens; and Standard 8, knowledge gaps identified from active AE monitoring should be systematically addressed through clinical research. These standards provide a person-centred, consensus-based approach to minimise the impact of AE during TB treatment. |
| Author | Udwadia, Z F Vu, D H Seaworth, B Stocker, S L Munoz Torrico, M Carvalho, A C C Margineanu, I Schaaf, H S Nunes, E Solovic, I Singla, R Palmero, D J Simonsson, U S H Caminero, J A Märtson, A-G Nataprawira, H M Hu, Y Borisov, S Peloquin, C A Ruslami, R Centis, R Bolhuis, M S Bhavani, P K Ong, C W M Trubiano, J Thomas, T A Furin, J Skrahina, A Tadolini, M Garcia-Prats, A Carvalho, I Dheda, K Rendon, A Rossato Silva, D Hesseling, A C D Ambrosio, L Alffenaar, J W C Bruchfeld, J Manga, S Verhage, A R Heysell, S K Davies Forsman, L Marais, B J García-García, J M Kim, H Y Akkerman, O W Saktiawati, A M I Migliori, G B Aarnoutse, R E Aleksa, A Santoso, P Mpagama, S G Dooley, K Cho, J G Sturkenboom, M G G Denholm, J T Tiberi, S Otto-Knapp, R Singh, K P van T Boveneind-Vrubleuskaya, N Dedicoat, M Svensson, E M Nguyen, B C Srivastava, S van Altena, R |
| Author_xml | – sequence: 1 givenname: K P surname: Singh fullname: Singh, K P organization: Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Victorian Infectious Disease Unit, Royal Melbourne Hospital, VIC, Australia – sequence: 2 givenname: A C C surname: Carvalho fullname: Carvalho, A C C organization: Laboratório de Inovações em Terapias, Ensino e Bioprodutos (LITEB), Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil – sequence: 3 givenname: R surname: Centis fullname: Centis, R organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy – sequence: 4 givenname: L surname: D Ambrosio fullname: D Ambrosio, L organization: Public Health Consulting Group, Lugano, Switzerland – sequence: 5 givenname: G B surname: Migliori fullname: Migliori, G B organization: Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy – sequence: 6 givenname: S G surname: Mpagama fullname: Mpagama, S G organization: Kilimanjaro Christian Medical University College, Moshi, United Republic of Tanzania, Kibong´oto Infectious Diseases Hospital, Sanya Juu, Siha, Kilimanjaro, United Republic of Tanzania – sequence: 7 givenname: B C surname: Nguyen fullname: Nguyen, B C organization: Woolcock Institute of Medical Research, Viet Nam and University of Sydney, NSW, Australia – sequence: 8 givenname: R E surname: Aarnoutse fullname: Aarnoutse, R E organization: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands – sequence: 9 givenname: A surname: Aleksa fullname: Aleksa, A organization: Grodno State Medical University, Grodno, Belarus – sequence: 10 givenname: R surname: van Altena fullname: van Altena, R organization: Asian Harm Reduction Network (AHRN) and Medical Action Myanmar (MAM), Yangon, Myanmar – sequence: 11 givenname: P K surname: Bhavani fullname: Bhavani, P K organization: Indian Council of Medical Research-National Institute for Research in Tuberculosis, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 12 givenname: M S surname: Bolhuis fullname: Bolhuis, M S organization: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 13 givenname: S surname: Borisov fullname: Borisov, S organization: Moscow Research and Clinical Center for Tuberculosis Control, Moscow, Russia – sequence: 14 givenname: N surname: van T Boveneind-Vrubleuskaya fullname: van T Boveneind-Vrubleuskaya, N organization: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands, Department of Public Health TB Control, Metropolitan Public Health Services, The Hague, The Netherlands – sequence: 15 givenname: J surname: Bruchfeld fullname: Bruchfeld, J organization: Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden – sequence: 16 givenname: J A surname: Caminero fullname: Caminero, J A organization: Department of Pneumology. University General Hospital of Gran Canaria "Dr Negrin", Las Palmas, Spain, ALOSA (Active Learning over Sanitary Aspects) TB Academy, Spain – sequence: 17 givenname: I surname: Carvalho fullname: Carvalho, I organization: Paediatric Department, Vila Nova de Gaia Hospital Centre, Vila Nova de Gaia Outpatient Tuberculosis Centre, Vila Nova de Gaia, Portugal – sequence: 18 givenname: J G surname: Cho fullname: Cho, J G organization: Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, Parramatta Chest Clinic, Parramatta, NSW, Australia – sequence: 19 givenname: L surname: Davies Forsman fullname: Davies Forsman, L organization: Departement of Medicine Solna, Division of Infectious Diseases, Karolinska Institutet, Stokholm, Sweden, Departement of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 20 givenname: M surname: Dedicoat fullname: Dedicoat, M organization: Department of Infectious Diseases, Heartlands Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK – sequence: 21 givenname: K surname: Dheda fullname: Dheda, K organization: Centre for Lung Infection and Immunity Unit, Department of Medicine, Division of Pulmonology and UCT Lung Institute, University of Cape Town, Cape Town, South Africa, South African Medical Research Council Centre for the Study of Antimicrobial Resistance, University of Cape Town, Cape Town, South Africa, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK – sequence: 22 givenname: K surname: Dooley fullname: Dooley, K organization: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA – sequence: 23 givenname: J surname: Furin fullname: Furin, J organization: Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA – sequence: 24 givenname: J M surname: García-García fullname: García-García, J M organization: Tuberculosis Research Programme, SEPAR (Sociedad Española de Neumología y Cirugía Torácica), Barcelona, Spain – sequence: 25 givenname: A surname: Garcia-Prats fullname: Garcia-Prats, A organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa, Department of Pediatrics, University of Wisconsin, Madison, WI, USA – sequence: 26 givenname: A C surname: Hesseling fullname: Hesseling, A C organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa – sequence: 27 givenname: S K surname: Heysell fullname: Heysell, S K organization: Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA – sequence: 28 givenname: Y surname: Hu fullname: Hu, Y organization: Department of Epidemiology, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China – sequence: 29 givenname: H Y surname: Kim fullname: Kim, H Y organization: Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 30 givenname: S surname: Manga fullname: Manga, S organization: Tuberculosis Department Latin American Society of Thoracic Diseases, Lima, Peru – sequence: 31 givenname: B J surname: Marais fullname: Marais, B J organization: Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Department of Infectious Diseases and Microbiology, The Children´s Hospital at Westmead, Westmead, NSW, Australia – sequence: 32 givenname: I surname: Margineanu fullname: Margineanu, I organization: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 33 givenname: A-G surname: Märtson fullname: Märtson, A-G organization: Centre of Excellence in Infectious Diseases Research, Antimicrobial Pharmacodynamics and Therapeutics Group, Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK – sequence: 34 givenname: M surname: Munoz Torrico fullname: Munoz Torrico, M organization: Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias, México City, Mexico – sequence: 35 givenname: H M surname: Nataprawira fullname: Nataprawira, H M organization: Division of Paediatric Respirology, Department of Child Health, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia – sequence: 36 givenname: E surname: Nunes fullname: Nunes, E organization: Department of Pulmonology of Central Hospital of Maputo, Maputo, Mozambique, Faculty of Medicine of Eduardo Mondlane University, Maputo, Mozambique – sequence: 37 givenname: C W M surname: Ong fullname: Ong, C W M organization: Infectious Disease Translational Research Programme, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Tradate, Italy, Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore – sequence: 38 givenname: R surname: Otto-Knapp fullname: Otto-Knapp, R organization: German Central Committee Against Tuberculosis (DZK), Berlin, Germany – sequence: 39 givenname: D J surname: Palmero fullname: Palmero, D J organization: Hospital Muniz and Instituto Vaccarezza, Buenos Aires, Argentina – sequence: 40 givenname: C A surname: Peloquin fullname: Peloquin, C A organization: Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy and Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA – sequence: 41 givenname: A surname: Rendon fullname: Rendon, A organization: Universidad Autonoma de Nuevo Leon, Facultad de Medicina, Neumología, CIPTIR, Monterrey, Mexico – sequence: 42 givenname: D surname: Rossato Silva fullname: Rossato Silva, D organization: Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil – sequence: 43 givenname: R surname: Ruslami fullname: Ruslami, R organization: TB/HIV Research Centre, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia – sequence: 44 givenname: A M I surname: Saktiawati fullname: Saktiawati, A M I organization: Department of Internal Medicine, Faculty of Medicine, Public Health, and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia, Centre for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia – sequence: 45 givenname: P surname: Santoso fullname: Santoso, P organization: Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia – sequence: 46 givenname: H S surname: Schaaf fullname: Schaaf, H S organization: Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Tygerberg, South Africa – sequence: 47 givenname: B surname: Seaworth fullname: Seaworth, B organization: University of Texas Health Science Center at Tyler, Tyler, TX, USA – sequence: 48 givenname: U S H surname: Simonsson fullname: Simonsson, U S H organization: Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden – sequence: 49 givenname: R surname: Singla fullname: Singla, R organization: Department of TB & Respiratory Diseases, National Institute of TB & Respiratory Diseases, New Delhi, India – sequence: 50 givenname: A surname: Skrahina fullname: Skrahina, A organization: Republican Research and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus – sequence: 51 givenname: I surname: Solovic fullname: Solovic, I organization: National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Faculty of Health, Catholic University, Ružomberok, Vyšné Hágy, Slovakia – sequence: 52 givenname: S surname: Srivastava fullname: Srivastava, S organization: University of Texas Health Science Center at Tyler, Tyler, TX, USA, Department of Medicine, The University of Texas at Tyler School of Medicine, TX, USA, Department of Pharmacy Practice, Texas Tech University Health Science Center, Dallas, TX, USA – sequence: 53 givenname: S L surname: Stocker fullname: Stocker, S L organization: School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Department of Clinical Pharmacology and Toxicology, St Vincent´s Hospital, Sydney, NSW, Australia – sequence: 54 givenname: M G G surname: Sturkenboom fullname: Sturkenboom, M G G organization: Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 55 givenname: E M surname: Svensson fullname: Svensson, E M organization: Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands, Department of Pharmacy, Uppsala University, Uppsala, Sweden – sequence: 56 givenname: M surname: Tadolini fullname: Tadolini, M organization: Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant´Orsola, Bologna, Italy, Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy – sequence: 57 givenname: T A surname: Thomas fullname: Thomas, T A organization: Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, VA, USA – sequence: 58 givenname: S surname: Tiberi fullname: Tiberi, S organization: Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK – sequence: 59 givenname: J surname: Trubiano fullname: Trubiano, J organization: Department of Infectious diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia, Department of Infectious Diseases, Austin Hospital, Melbourne, VIC, Australia – sequence: 60 givenname: Z F surname: Udwadia fullname: Udwadia, Z F organization: P. D. Hinduja National Hospital and Medical Research Centre, Mumbai, India – sequence: 61 givenname: A R surname: Verhage fullname: Verhage, A R organization: Department of Paediatrics, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands – sequence: 62 givenname: D H surname: Vu fullname: Vu, D H organization: National Drug Information and Adverse Drug Reaction Monitoring Centre, Hanoi University of Pharmacy, Hanoi, Vietnam – sequence: 63 givenname: O W surname: Akkerman fullname: Akkerman, O W organization: Department of Pulmonary Diseases and Tuberculosis, Groningen, Haren, the Netherlands, Tuberculosis Center Beatrixoord, University Medical Center Groningen, University of Groningen, Haren, the Netherlands – sequence: 64 givenname: J W C surname: Alffenaar fullname: Alffenaar, J W C organization: Sydney Infecious Diseases Institute (Sydney ID), The University of Sydney, Sydney, NSW, Australia, Westmead Hospital, Sydney, NSW, Australia, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia – sequence: 65 givenname: J T surname: Denholm fullname: Denholm, J T |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37353868$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAYhC1URGlhZEUeWVr80cT2CBVfUiUYyhy9sV-XVIlTbAeJf0-BIjHdSffcDTcho9AHJOSCs3lRaH3dbHPr5kLOGVP6iJxyzYuZMoKN_vkxmaS0ZUxwztUJGUslC6lLfUpelm0TGgstTRmCg-gS9X2k-Q1pBwE22GHItPcU3AfGhBS9R5sTdUNswobmiJB_mO_a-vaMHHtoE54fdEpe7-_Wy8fZ6vnhaXmzmtmiEHkmGZZGyLLWC89LzVThSmb2mYQaam-sh1opMEoDt7a2emEMWPSmlko5tGJKrn53d7F_HzDlqmuSxbaFgP2QKqGFWQhTcrNHLw_oUHfoql1sOoif1d8L4gvMt2GC |
| CitedBy_id | crossref_primary_10_1016_j_cmi_2024_10_013 crossref_primary_10_1183_13993003_00109_2024 crossref_primary_10_1016_j_cmi_2025_08_020 crossref_primary_10_4102_sajid_v38i1_564 crossref_primary_10_3390_antibiotics14010007 crossref_primary_10_1016_j_eclinm_2025_103148 crossref_primary_10_1016_j_sapharm_2024_08_091 crossref_primary_10_5588_ijtldopen_24_0613 crossref_primary_10_3390_medicina61050911 crossref_primary_10_5588_ijtldopen_23_0623 crossref_primary_10_1007_s11904_025_00746_z crossref_primary_10_1016_j_jaip_2024_07_034 crossref_primary_10_1186_s12906_024_04632_w crossref_primary_10_3390_tropicalmed10070176 crossref_primary_10_4103_apjtm_apjtm_72_24 crossref_primary_10_5588_ijtldopen_23_0587 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.5588/ijtld.23.0078 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1815-7920 |
| ExternalDocumentID | 37353868 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI137080 – fundername: NIAID NIH HHS grantid: U01 AI150508 – fundername: NIAID NIH HHS grantid: K24 AI150349 – fundername: NIAID NIH HHS grantid: P30 AI036214 |
| GroupedDBID | --- ..I 29J 2WC 5GY 5RE ACGFO ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CUY CVF DIK DU5 EBS ECM EIF EJD F5P H13 IPNFZ NPM OK1 P2P PQQKQ RIG TR2 7X8 |
| ID | FETCH-LOGICAL-c552t-30e69236b84f168075d609c553ababf9cfab77a978a1ccbc8499acef9b377dec2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001029744100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1815-7920 |
| IngestDate | Sat Nov 01 14:58:04 EDT 2025 Sat Nov 22 01:41:03 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c552t-30e69236b84f168075d609c553ababf9cfab77a978a1ccbc8499acef9b377dec2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-509152 |
| PMID | 37353868 |
| PQID | 2829429619 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2829429619 pubmed_primary_37353868 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-07-01 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | France |
| PublicationPlace_xml | – name: France |
| PublicationTitle | The international journal of tuberculosis and lung disease |
| PublicationTitleAlternate | Int J Tuberc Lung Dis |
| PublicationYear | 2023 |
| SSID | ssj0021117 |
| Score | 2.4943993 |
| Snippet | Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise... BACKGROUND: Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 506 |
| SubjectTerms | Drug-Related Side Effects and Adverse Reactions - etiology Health Personnel Humans Hypersensitivity Tuberculosis - diagnosis Tuberculosis - drug therapy |
| Title | Clinical standards for the management of adverse effects during treatment for TB |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37353868 https://www.proquest.com/docview/2829429619 |
| Volume | 27 |
| WOSCitedRecordID | wos001029744100004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwED4BRYiF96O8ZCTWQGMnsTMhQFQsrToUqVvkp1QESSGF3885ccuEhMSSJbGUnM_n73yX7wO4irmksTaYptpMRElKTSSFyHDFG4TLrpdTKRuxCT4ciskkH4UDtzq0VS5iYhOoTaX9GfmNr_hh7ES8fzt7j7xqlK-uBgmNVegwhDLeq_lkWUXA3KZR3MVNzNMy0l7LsZmmmPRNX-av5pp6elMufkeXzS7T3_7v--3AVsCX5K51iF1YseUebAxCBX0fRoEI9JUsDhFqgriVIA4kb8tWGFI5Ir1Uc21J6Pgg7Q-NZNmZ3gwb3x_Ac_9x_PAUBVWFSKcpnUcMZwVRXaZE4uLMcxHjrOR4j0kllcu1k4pzidmljLVWWmBOJLV1uWKcG6vpIayVVWmPgeD3Gke1MggDE4WPOJ0Iw0wu49RgKO3C5cJWBXqtL0XI0lafdfFjrS4ctQYvZi29RsE4wyiciZM_jD6FTa__3vbPnkHH4Zq157Cuv-bT-uOicQe8DkeDbzBkwKk |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+standards+for+the+management+of+adverse+effects+during+treatment+for+TB&rft.jtitle=The+international+journal+of+tuberculosis+and+lung+disease&rft.au=Singh%2C+K+P&rft.au=Carvalho%2C+A+C+C&rft.au=Centis%2C+R&rft.au=D+Ambrosio%2C+L&rft.date=2023-07-01&rft.issn=1815-7920&rft.eissn=1815-7920&rft.volume=27&rft.issue=7&rft.spage=506&rft_id=info:doi/10.5588%2Fijtld.23.0078&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1815-7920&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1815-7920&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1815-7920&client=summon |